NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£262M
Sector
HEALTH
Published
14 Mar 2023
Delivery
01 Mar 2023 to 28 Feb 2025
Deadline
24 Oct 2022 12:00

Concepts

Location

Geochart for 1 buyers and 29 suppliers

1 buyer

29 suppliers

Description

NHS Framework for North of England Branded Medicines - Tranche A and Annual Tranche. Offer reference number: CM/PHR/20/5606 CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5606/02 - NHS Framework for North of England Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5606/03 - NHS National Framework Agreement for the supply of Risankizumab for South of England and London. Period of framework: 1 March 2023 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months

Award Detail

1 Roche Products (Welwyn Garden City)
  • Value: £261,970,000
2 Sandoz (Camberley)
  • Value: £261,970,000
3 Teva (Castleford)
  • Value: £261,970,000
4 Celltrion Healthcare (Slough)
  • Value: £261,970,000
5 Merck Sharpe & Dohme (London)
  • Value: £261,970,000
6 Chugai Pharma (None)
  • Value: £261,970,000
7 Amgen (Cambridge)
  • Value: £261,970,000
8 Janssen Cilag (Highwycombe)
  • Value: £261,970,000
9 Accord (Barnstaple)
  • Value: £261,970,000
10 Pfizer (Sandwich)
  • Value: £261,970,000
11 Thornton & Ross (Huddersfield)
  • Value: £261,970,000
12 Glaxosmithkline (London)
  • Value: £261,970,000
13 Abbvie (Maidenhead)
  • Value: £261,970,000
14 Aventis Pharma (Reading)
  • Value: £261,970,000
15 Ipsen (Slough)
  • Value: £261,970,000
16 Astrazeneca (London)
  • Value: £261,970,000
17 Pharmacosmos (Reading)
  • Value: £261,970,000
18 Takeda (London)
  • Value: £261,970,000
19 Merck Serono (Feltham)
  • Value: £261,970,000
20 Organon Pharmaceuticals (London)
  • Value: £261,970,000
21 Zentiva Pharma (London)
  • Value: £261,970,000
22 Novo Nordisk (Gatwick)
  • Value: £261,970,000
23 Merz (Hemel Hempstead)
  • Value: £261,970,000
24 Eli Lilly (Hants)
  • Value: £261,970,000
25 Vifor Pharma (London)
  • Value: £261,970,000
26 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £261,970,000
27 Gedeon Richter (London)
  • Value: £261,970,000
28 Almirall (Uxbridge)
  • Value: £261,970,000
29 Ucb Pharma (Slough)
  • Value: £261,970,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

5606 02 Transparency Award Schedule 5606 02 Transparency Award Schedule.pdf 5606 03 Transparency Award Schedule 5606 03 Transparency Award Schedule.pdf Document No. 03 - Framework Agreement and Terms and Conditions Document No. 03 - Framework Agreement and Terms and Conditions.pdf 5606 01 Transparency Award Schedule 5606 01 Transparency Award Schedule.pdf Parties Appointed to the Framework Agreement - CM_PHR_20_5606 North of England Parties Appointed to the Framework Agreement - CM_PHR_20_5606 North of England.xlsx Document No. 10 - Participating Authorities Document No. 10 - Participating Authorities.xls FTS OPPORTUNITY NOTICE - 026723-2022 CM-PHR-20-5606 - NHS Framework for North of England Branded Medicines - Tranche A FTS OPPORTUNITY NOTICE - 026723-2022 CM-PHR-20-5606 - NHS Framework for North of England Branded Medicines - Tranche A.pdf

Reference

Domains